Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.59 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | IL1B | P01584 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371187 | 0.91 | CNR1 (0.48) | CNR1CNR2IL1BP2RX7TRPV1 | |
| SCHEMBL4371310 | 0.91 | CNR1 (0.48) | CNR1CNR2IL1BP2RX7TRPV1 | |
| SCHEMBL4371181 | 0.91 | CNR1 (0.48) | CNR1CNR2IL1BP2RX7TRPV1 | |
| SCHEMBL4367965 | 0.90 | CNR1 (0.59) | CNR1CNR2CCR2TRPV1CHRM3 | |
| SCHEMBL4372529 | 0.85 | CNR1 (0.42) | CNR1CNR2IL1BP2RX7TRPV1 | |
| SCHEMBL5615341 | 0.81 | CNR1 (0.66) | CNR1CNR2CCR2TRPV1CHRM1 | |
| SCHEMBL4372545 | 0.80 | CNR1 (0.48) | CNR1CNR2RORCLMNANPSR1 | |
| SCHEMBL4374615 | 0.80 | CNR1 (0.48) | CNR1CNR2RORCLMNANPSR1 | |
| SCHEMBL13717371 | 0.80 | CNR1 (0.67) | CNR1CNR2TRPV1CHRM1 | |
| SCHEMBL4374797 | 0.77 | ALDH1A1 (0.43) | CNR1CNR2RORCLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885CCR2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.